Vanda Pharmaceuticals Inc. (VNDA) is set to face a pivotal FDA decision on February 21, 2026, for its drug candidate Bysanti.
Bysanti is proposed for the treatment of bipolar I disorder and schizophrenia, two major psychiatric indications with significant unmet needs. This drug candidate (milsaperidone) is an active metabolite of iloperidone, marketed as Fanapt.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com